APLLTD.NSE · Alembic Pharmaceuticals Limited

-

Please sign in to comment on APLLTD.NSE

1 Comment

Admin

4 years ago

Alembic Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 0.6% above its 200 day moving average.

From a valuation standpoint, the stock is 24.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.

Alembic Pharmaceuticals Limited's total revenue rose by 8.7% to $13B since the same quarter in the previous year.

Its net income has increased by 24.9% to $3B since the same quarter in the previous year.

Finally, its free cash flow grew by 582.7% to $9B since the same quarter in the previous year.

Based on the above factors, Alembic Pharmaceuticals Limited gets an overall score of 5/5.

Exchange	NSE
CurrencyCode	INR
ISIN	INE901L01018
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Market Cap	172B
PE Ratio	28.49
Target Price	1054.6364
Dividend Yield	1.3%
Beta	0.69

ABOUT

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

APLLTD.NSE · Alembic Pharmaceuticals Limited

-

Alembic Pharmaceuticals Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Alembic Pharmaceuticals Limited using a moving average strategy